INDEPENDENT IPO / PLACEMENT / LOCKUP RESEARCH - US & APAC

The ECM Research
you won’t get from the banks

Aequitas delivers independent analysis of US & APAC IPOs, placements and lock-up expiries for institutional investors.

We cover every US and APAC deal over US$100m, from pre-IPO to listing and lockups.

Excludes biotech. APAC includes Hong Kong, China ADRs, India, ASEAN, South Korea, Japan, Australia, New Zealand, and Asia-linked cross-border listings

1,072

TRACK RECORD (as at 28 October 2026)

IPOs covered since 2015

1,699

Placements covered since 2015

~60%

of covered IPOs rated ‘avoid’

as at 28 October 2026

73%

IPO call accuracy

Fundamental, bottom-up research

Proprietary quantitative framework

Consistent analysis at every stage

The ECM Research
you won’t get from the banks

Aequitas delivers independent analysis of US & APAC IPOs, placements and lock-up expiries for institutional investors.

We cover every US and APAC deal over US$100m, from pre-IPO to listing and lockups.

1,072

1,699

~60%

73%

No. of IPOs and Placements Covered

Accuracy Rates (%)

The ECM Research you won’t get from the banks

Aequitas delivers independent analysis of US & APAC IPOs, placements and lock-up expiries for institutional investors.

We cover every US and APAC deal over US$100m, from pre-IPO to listing and lockups.

1,072

1,699

~60%

73%

No. of IPOs and Placements Covered

Accuracy Rates (%)

The ECM Research
you won’t get from the banks